Date post: | 02-Jan-2016 |
Category: |
Documents |
Upload: | hayes-chase |
View: | 18 times |
Download: | 5 times |
Exclusive strategic partnership agreement with Sumitomo Corp. to develop, market and sell the natural Vitamin K2
Exclusive Research & Science contract with VitaK (Maastricht University), the world leading research-company in vitamin K.
R&D is focused on developing K2 products in addition to build IPR to secure long-term market access
Vitamin K2 is needed for optimal body utilization of Calcium and has documented beneficial effects on both Osteoporosis and Cardiovascular diseases
NattoPharma focuses on Sales & Product Development, through own Product IPR- based on clinical studies (GCP), leaving the production to Sumitomo.
Product development may also be carried out in collaboration with End-clients, depending upon customer and market requirements.
Production& Process IPR
Sumitomo Corp.
Product-Development
Based on research
NattoPharma
Product-design End-product S&M
End-client
Clinical StudiesIPR
Calcification in health and disease:NattoPharma focus
Normal condition:99% of all Ca inbones & teeth;1% in circulation
Scientific evidence:Loss of calcification in bones;Increased calcification heart,arteries and in joints:
•Osteoporosis•Cardiovascular disease•Osteoarthrosis
Kidneys
Lungs
+- +
+
Teeth
Bone and cardiovascular health
Prevention &Treatment
The calcium paradoxRelationship osteoporosis - arterial calcification
Function of both proteins needed for optimal health
•OC synthesised in osteoblasts• Glu residues carboxylated to Gla-residues which bind Ca++
• Binds Ca++ to hydroxyapatite in bones
•MGP synthesised in chondrocytes in cartilage, and vascular smooth muscle cells in arteries•Inhibits soft tissue calcification, including
cartilage mineralization
Matrix Gla ProteinOsteocalcin
x xx
Market opportunities
NattoPharma market strategy
• NattoPharma is working to include vitamin K2 in already existing global leading brands in the Dietary supplement (ex. Multivitamins, Calsium & Omega3) Functional Food marked (Dairy-products). Thus, the revenue from the clients has the potential to go from zero to 3-diget million figure, only during the first year after signing with a large client.
Dietary supplement
• Stand-alone / combination (Multivitamins, Calcium, Omega-3 and Vitamin D)
Fortified food
• Fortified food with vitamins and minerals (Dairy segment, drinks)
Pharmacy
• Strategy is to co-operate with a strategic partner
Market strategySell MenaQ7 as an ingredients into all ready existing global leading brands in the following market segments:
2007 2008 2009 2010 2011 2012 2013
Vo
lum
vit
am
in K
2
Dietary supplement
Fortified Food
Pharmacy
Headlines 1Q08
R&D:Commenced clinical study combining
MenaQ7 with Omega- and with KrillLongtime study approved and ready to
start for postmenopausal 240 women to see MenaQ7’s effect on bone structure and cardio vascular effects.
Headlines 1Q08
MARKET:Have signed distribution agreements in all
European countries that we are able to MenaQ7Focus on Food segment both in USA. Official
launch of MenaQ7 in Food at world larges Food Fair, Institute of Food Technology 2008 in New Orleans.
Screening the market outside Europe and USA for potential distributors
Strategic Partnership Agremments
• LOI sign with Bayer ConsumerCare– Bayer is no. 2 largest player in the global OTC
market– The Parties wants to negotiate about signing
a global partnership agreement for MenaQ7.
• In search for a global partner also in the Food Market
Figures 1. quarter 2008
Revenues NOK 5,1m (NOK 7,4m)EBIT NOK -5,9m (NOK -0,8m)Gross margin 55,1% (56,4%)
Profit and Loss pr.31.03.2008INCOME STATEMENT BY NATURE
OF EXPENSE01.01-
31.03.08
01.01-31.03.07 Noter
01.01-31.03.08
01.01-31.03.07
01.01-31.12.07
REVENUE
5 165 7 302 2 Revenue 5 165 7 302 22 1270 98 Other income 0 98 258
5 165 7 400 TOTAL REVENUE 5 165 7 400 22 385
OPERATING EXPENSES
2 321 3 230 Raw material and consumable goods 2 321 3 230 9 3112 447 1 321 Employee benefits expense 2 447 1 321 5 677
598 38 3 Depreciation nad amortisation expenses 598 38 4815 714 3 581 Other operating expenses 5 714 3 581 13 090
11 080 8 170 TOTAL OPERATING EXPENSES 11 080 8 170 28 559
-5 915 -770 OPERATING PROFIT/LOSS -5 915 -770 -6 174
FINANCIAL INCOME AND EXPENSES
252 7 Finance income 252 7 42387 0 Other finance income 87 0 0
456 1 Finance costs 456 1 1 43779 339 Other finance costs 79 339 840
-196 -333 NET FINANCE -196 -333 -1 854
-6 111 -1 103 LOSS BEFORE INCOME TAX -6 111 -1 103 -8 028
-1 486 -309 Income tax expense -1 486 -309 2 172
-4 625 -794 NET PROFIT/LOSS -4 625 -794 -5 856
Result and diluted result per shareassigned to the company's shareholders:
-0,23 -0,05 6 Result and diluted result per share -0,15
NattoPharma ASA NattoPharma consolidated
Balance pr. 31.03.2008ASSETS
31.03.2008 31.03.2007 Notes 31.03.2008 31.03.2007
NON CURRENT ASSETS
INTANGIBLE ASSETS5 391 2 513 Deferred tax 5 391 2 5134 486 1 637 3 Other intangible assets 4 486 1 7939 877 4 150 Total intangible assets 9 877 4 306
TANGIBEL ASETS352 973 Equipment 352 973352 973 Total tangible assets 352 973
FINANCIEL ASSETS0 156 Investment in subsidiaries 0 00 156 Total financial assets 0 0
10 229 5 279 TOTAL NON CURRENT ASSETS 10 229 5 279
CURRENT ASSETS184 0 Warehouse 184 0
2 774 1 119 Accounts receivables 2 774 1 1191 038 346 Prepaid costs 1 038 346
252 31 Other short term receivables 252 3124 063 6 051 Cash and cash equivalents 24 063 6 051
28 311 7 547 TOTAL CURRENT ASSEST 28 311 7 547
38 540 12 826 TOTAL ASSETS 38 540 12 826
NattoPharma ASA NattoPharma consolidated
Balance pr. 31.03.2008EQUITY AND LIABILITIES
31.03.2008 31.03.2007 Notes 31.03.2008 31.03.2007 EQUITY
OWNERS EQUITY2 045 1 878 Share capital 2 045 1 878
0 0 Resolved, not registered share increase 0 032 680 16 661 Share premium reserve 32 680 16 661
1 431 155 Other paid in equity 1 431 15536 156 18 694 Total owners equity 36 156 18 694
EARNED EQUITY-16 173 -6 486 Accumulated loss -16 173 -6 486
19 983 12 208 TOTAL EQUITY 19 983 12 208
LIABILITIES13 390 0 4 Long term debt 13 390 013 390 0 Total long term debt 13 390 0
CURRENT LIABILITIES3 307 91 Accounts payable 3 307 91
527 301 Public duties payable 527 3011 333 226 5 Other short term debt 1 333 2265 167 618 Total current liabilities 5 167 618
18 557 618 TOTAL LIABILITIESSUM GJELD 18 557 618
38 540 12 826 TOTAL EQUITY AND LIABILITIES 38 540 12 826
NattoPharma ASA NattoPharma consolidated
Cash flow statement Q1 - 2008
2008 200701.01.-31.03 01.01.-31.03
Net Cash Flow from Operations (5 121) (1 123)
Purchase of tangible - (156) Purchase of intangible - (572) Purchase of company - -
Net cash flow from investment - (728)
Payment from issue of shares 15 011 - Payment from issue of bonds - Purchase of own bonds (3 013) Payment from issue of warrants - Payment from excersising share options -
Net cash flow from financial activities 11 998 -
Net change in cash and cash equivalents 6 877 (1 851) Cash and Cash equivalents as pr. 1.1. 17 186 7 902 Cash and Cash equivalents as pr. 31.03. 24 063 6 051